ANCA ASSOCIATED VASCULITIS (AAV)
Clinical trials for ANCA ASSOCIATED VASCULITIS (AAV) explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS (AAV) trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test One-Shot cell therapy to reset the immune system in autoimmune patients
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called RD06-05 for people with active autoimmune diseases. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remove harmful immune cells, aiming to reset the immune system. The main…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Experimental cell therapy tested in children with devastating immune diseases
Disease control Recruiting nowThis early-stage clinical trial is testing an experimental cell therapy called Descartes-08 in children, teens, and young adults with several rare and serious autoimmune diseases. The study aims to find a safe dose and see if the treatment helps control these conditions, which in…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial aims to tame dangerous autoimmune attack
Disease control Recruiting nowThis study is testing whether adding an investigational drug called BDB-001 to standard treatments helps people with active ANCA-associated vasculitis (AAV) achieve and maintain disease remission. It will involve about 300 adults with this serious autoimmune condition. Researcher…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
One-Shot cell therapy tested as potential reset for stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a single infusion of 'universal' CAR T-cells in adults with severe autoimmune diseases like lupus and scleroderma that have not improved with standard treatments. The therapy aims to target and remove harmful immune cells to potentially control t…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Engineered immune cells target devastating autoimmune diseases in groundbreaking trial
Disease control Recruiting nowThis early-stage study is testing a new cell therapy for people with severe autoimmune diseases that haven't improved with standard treatments. Doctors will give patients specially engineered immune cells (CAR-NK cells) to try to reset their overactive immune systems. The main go…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Mar 18, 2026 14:55 UTC
-
CAR-T therapy trial aims to tame devastating autoimmune attack
Disease control Recruiting nowThis study is testing a new type of treatment called rapcabtagene autoleucel, a CAR-T cell therapy, for people with severe forms of two autoimmune diseases that cause blood vessel inflammation (GPA and MPA). It will compare this one-time cell therapy to standard treatments to see…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Scientists test 'Off-the-Shelf' cell therapy to reset immune system in devastating autoimmune diseases
Disease control Recruiting nowThis early-phase study is testing a new type of cell therapy called QT-019C for people with severe autoimmune diseases that have not improved with standard treatments. The therapy uses donated, 'universal' immune cells engineered to target and remove harmful immune cells. The mai…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Blood test could end arthritis medication guesswork
Diagnosis Recruiting nowThis study is testing a new blood test designed to predict which arthritis medications will work best for individual patients before they start treatment. Researchers will analyze blood samples from 120 people with various autoimmune rheumatic diseases to see if the test can accu…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Bonn • Aim: Diagnosis
Last updated Apr 01, 2026 14:43 UTC
-
New scans could reveal hidden dangers in rare autoimmune disease
Knowledge-focused Recruiting nowThis study aims to see if a new type of full-body scan (PET scan) can better detect active disease and predict future heart disease risk in people with ANCA-associated vasculitis (AAV), a serious autoimmune condition. Researchers will compare scan results from about 120 people—so…
Matched conditions: ANCA ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC